We are dropping coverage of BioMed Realty Trust . We cover a selection of roughly 1,500 stocks and adjust our coverage as necessary based on client demand and investor interest.
A number of moving parts influenced year-over-year comparisons in life-science landlord BioMed's first-quarter results, but overall results are tracking near our expectations, and we're maintaining both our $20 fair value estimate and our no-moat rating for the firm. For the quarter, on a ...
Lab and research space landlord BioMed Realty Trust reported fourth-quarter results that were near our expectations. We're maintaining both our $20 fair value estimate and no
Life sciences landlord BioMed Realty Trust reported solid headline growth due largely to its recent acquisition of Wexford's portfolio, but after accounting for incremental
Hi folks, Josh just sold off BMR , WM and WR He also bought GSK, RCI and SO. Thought on these moves? I already sold WR a couple months ago and never held BMR or WM. Now I am looking at his buys. SO looks like a very solid
We are lowering our moat rating for BioMed Realty Trust BMR to none from narrow, because of higher estimated property maintenance expenditures. Incorporating higher property maintenance
We are placing BioMed Realty Trust BMR under review as we transfer coverage to a new analyst.
We are maintaining our $21 fair value estimate and narrow moat rating for BioMed Realty Trust BMR following its $640 million acquisition of privately held life sciences real estate peer Wexford Science & Technology. Although
Landlord to the life sciences industry BioMed Realty Trust BMR reported solid fourth-quarter results that were near our expectations, and we will not change our $21 fair value estimate
day with 11% cash in my income portfolio and ended it with about 8% biding my time. Added to Intel $21.31 ~ 4.2% div Added to REIT BMR $19.30 ~ 4.5% div Added to KMP $84.89 They raised their div today to $5.04 ~5.9% Nick